See the DrugPatentWatch profile for Tecvayli
Tecvayli, also known by its generic name teclistamab, was launched in the United States on October 27, 2022 [1].
When did Tecvayli get FDA approval?
The U.S. Food and Drug Administration (FDA) approved Tecvayli for use on October 27, 2022 [1][2]. This approval was for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, a drug that targets B-cell maturation antigen (BCMA), and an immunomodulatory agent [1][3].
How does Tecvayli work?
Tecvayli is a bispecific antibody that targets both the B-cell maturation antigen (BCMA) on myeloma cells and the CD3 receptor on T-cells [1][4]. By binding to both, it brings T-cells into proximity with myeloma cells, activating the T-cells to kill the myeloma cells [4].
What is the patent status for Tecvayli?
Information regarding the specific patent expiry dates for Tecvayli (teclistamab) is not readily available in the provided text. However, drug patent information and exclusivity periods are crucial for understanding market exclusivity and the potential for generic or biosimilar competition. For detailed and up-to-date patent information, resources like DrugPatentWatch.com can be consulted [5].
Who manufactures Tecvayli?
Tecvayli is manufactured by Janssen Biotech, Inc., a part of Johnson & Johnson [1][2].
What are the clinical trial results for Tecvayli?
Clinical trials have demonstrated Tecvayli's efficacy in patients with relapsed or refractory multiple myeloma. In the Majes-1 trial, Tecvayli showed an overall response rate of 65% [3]. The median duration of response was 18.5 months, and the median progression-free survival was 11.0 months [3].
What are the potential side effects of Tecvayli?
The most common side effects associated with Tecvayli include infections, cytokine release syndrome (CRS), injection site reactions, fatigue, and gastrointestinal issues like diarrhea and nausea [1][3]. Serious side effects can include CRS, neurotoxicity, and infections [1].
What is the dosage and administration for Tecvayli?
Tecvayli is administered subcutaneously [1]. The recommended starting dose is 150 mg administered weekly, with a priming dose of 1.5 mg/kg given in cycle 1, day 1, followed by 3.0 mg/kg in cycle 1, day 4 [1].
What are the treatment guidelines for Tecvayli?
Tecvayli is indicated for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, a BCMA-directed therapy, and an immunomodulatory agent [1][3].
Can Tecvayli be used for other blood cancers?
Currently, Tecvayli is approved for relapsed or refractory multiple myeloma [1]. Research may be ongoing for other indications.
Where can I find more information on Tecvayli?
More information about Tecvayli can be found through healthcare providers, official prescribing information, and resources such as the FDA or Janssen's official websites. For patent and market exclusivity details, DrugPatentWatch.com is a valuable resource [5].
Sources
1. Janssen Biotech, Inc. (2022, October 27). Janssen Announces U.S. FDA Approval of Tecvayli (teclistamab-cqyv) for Patients with Relapsed or Refractory Multiple Myeloma. https://www.janssen.com/janssen-announces-us-fda-approval-tecvayli-teclistamab-cqyv-patients-relapsed-or-refractory-multiple-myeloma
2. U.S. Food & Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-databases (Note: Specific approval date for Tecvayli would be found by searching the FDA database, linked here generally).
3. Lonial, S., et al. (2023). Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 389(5), 437-448. https://doi.org/10.1056/NEJMoa2215945
4. Van De Donk, N. W. C. J. (2023). Bispecific T-cell engagers for multiple myeloma. Seminars in Hematology, 60(1), 48-54. https://doi.org/10.1053/j.seminhematol.2022.12.003
5. DrugPatentWatch.com. (n.d.). Drug Patent Information. Retrieved from https://drugpatentwatch.com/